On the hindering evolution of drug resistance due to intraspecific competition arising during the facilitation survival for non-genetic resistance with fractal fractional derivative order

Shikongo, Albert; Owolabi, Kolade M.

doi:10.1007/s40808-022-01644-8

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of the association between antibioticresistant bacterial colonization/infection using the WHO Access, Watch, and Reserve (AWaRe) classification revealed that LNZ had the highest correlation with the infection caused by the colonization of critical and high-priority multidrug-resistant organisms (MDROs) [27]. This change in drug resistance may be related to the world's climate change; it has been demonstrated that drug resistance evolves as a result of intraspecific competition during the facilitation of non-genetic resistance [28]. Traditional antibiotics are no longer effective in preventing and controlling multidrug-resistant enterococci, and new protocols for the control of linezolid-resistant enterococcal infections are urgently needed to address the major threat of enterococcal infections.…”

Section: Discussionmentioning

confidence: 99%

The Synergistic Activity of Rhamnolipid Combined with Linezolid against Linezolid-Resistant Enterococcus faecium

Chang,

Chen,

et al. 2023

Molecules

View full text Add to dashboard Cite

Enterococci resistance is increasing sharply, which poses a serious threat to public health. Rhamnolipids are a kind of amphiphilic compound used for its bioactivities, while the combination of nontraditional drugs to restore linezolid activity is an attractive strategy to treat infections caused by these pathogens. This study aimed to investigate the activity of linezolid in combination with the rhamnolipids against Enterococcus faecium. Here, we determined that the rhamnolipids could enhance the efficacy of linezolid against enterococci infections by a checkerboard MIC assay, a time–kill assay, a combined disk test, an anti-biofilm assay, molecular simulation dynamics, and mouse infection models. We identified that the combination of rhamnolipids and linezolid restored the linezolid sensitivity. Anti-biofilm experiments show that our new scheme can effectively inhibit biofilm generation. The mouse infection model demonstrated that the combination therapy significantly reduced the bacterial load in the feces, colons, and kidneys following subcutaneous administration. This study showed that rhamnolipids could play a synergistic role with linezolid against Enterococcus. Our combined agents could be appealing candidates for developing new combinatorial agents to restore antibiotic efficacy in the treatment of linezolid-resistant Enterococcus infections.

show abstract

Section: Discussionmentioning

confidence: 99%